NASDAQ:TCON - TRACON Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.60 -0.05 (-1.89 %) (As of 07/16/2018 04:00 PM ET)Previous Close$2.65Today's Range$2.55 - $2.6552-Week Range$2.00 - $3.95Volume68,284 shsAverage Volume162,995 shsMarket Capitalization$47.04 millionP/E Ratio-2.28Dividend YieldN/ABeta2.08 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc. for the development and commercialization of TRC105; and Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122 for the ophthalmology indications of TRC105, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California. Receive TCON News and Ratings via Email Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:TCON CUSIPN/A Webwww.traconpharma.com Phone858-550-0780 Debt Debt-to-Equity Ratio0.15 Current Ratio4.24 Quick Ratio4.24 Price-To-Earnings Trailing P/E Ratio-2.28 Forward P/E Ratio-2.10 P/E GrowthN/A Sales & Book Value Annual Sales$8.76 million Price / Sales5.27 Cash FlowN/A Price / CashN/A Book Value$0.96 per share Price / Book2.71 Profitability EPS (Most Recent Fiscal Year)($1.14) Net Income$-19,100,000.00 Net MarginsN/A Return on Equity-82.47% Return on Assets-47.74% Miscellaneous Employees25 Outstanding Shares17,750,000Market Cap$47.04 TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions What is TRACON Pharmaceuticals' stock symbol? TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON." How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals Inc (NASDAQ:TCON) released its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.10. The biopharmaceutical company earned $3 million during the quarter, compared to analysts' expectations of $3 million. View TRACON Pharmaceuticals' Earnings History. When is TRACON Pharmaceuticals' next earnings date? TRACON Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for TRACON Pharmaceuticals. What price target have analysts set for TCON? 1 brokerages have issued 12 month price targets for TRACON Pharmaceuticals' shares. Their forecasts range from $8.00 to $8.00. On average, they expect TRACON Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 207.7% from the stock's current price. View Analyst Ratings for TRACON Pharmaceuticals. What is the consensus analysts' recommendation for TRACON Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of TRACON Pharmaceuticals' key competitors? Some companies that are related to TRACON Pharmaceuticals include Fennec Pharmaceuticals (FENC), Krystal Biotech (KRYS), Compugen (CGEN), Organovo (ONVO), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX), Eiger Biopharmaceuticals (EIGR), Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Entera Bio (ENTX), Applied Genetic Technologies (AGTC), Genocea Biosciences (GNCA), Champions Oncology (CSBR), Curis (CRIS) and Aevi Genomic Medicine (GNMX). Who are TRACON Pharmaceuticals' key executives? TRACON Pharmaceuticals' management team includes the folowing people: Dr. Charles P. Theuer, CEO, Pres & Director (Age 54)Ms. Patricia L. Bitar, Chief Financial Officer, Treasurer and Assistant Sec. (Age 59)Mr. H. Casey Logan, Chief Bus. Officer (Age 46)Dr. Sharon Real Ph.D., Sr. VP of Product Devel. (Age 54)Ms. Bonne Adams M.B.A., Sr. VP of Clinical Operations (Age 41) When did TRACON Pharmaceuticals IPO? (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. Has TRACON Pharmaceuticals been receiving favorable news coverage? News stories about TCON stock have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a coverage optimism score of 0.14 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TRACON Pharmaceuticals' stock price today? One share of TCON stock can currently be purchased for approximately $2.60. How big of a company is TRACON Pharmaceuticals? TRACON Pharmaceuticals has a market capitalization of $47.04 million and generates $8.76 million in revenue each year. The biopharmaceutical company earns $-19,100,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. TRACON Pharmaceuticals employs 25 workers across the globe. How can I contact TRACON Pharmaceuticals? TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected] MarketBeat Community Rating for TRACON Pharmaceuticals (NASDAQ TCON)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 133 (Vote Underperform)Total Votes: 297MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote "Outperform" if you believe TCON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?